top of page

GENE EDITING


Series supported by Intellia Therapeutics



Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease

Laura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics



About Laura Sepp-Lorenzino


Safety considerations in therapeutic genome editing

Toni Cathomen, University of Freiburg






About Toni Cathomen


Repurposing of bacterial CRISPR-Cas immunity for genome editing

Virgis Siksnys, Vilnius University, Institute of Biotechnology


Video available to ESGCT members only



About Virgis Siksnys



Comentários


bottom of page